Northwire Canada EditionSaturday, November 7, 2026
Sign inSubscribe
Northwire
⌕
Gold 4,079.60 −0.8% Silver 51.94 −0.8% Copper 6.24 −0.5% Oil 90.83 +0.3% Palladium 1,017.10 −2.6% KRN 0.260 −7.1% GSKR 2.84 +5.6% ADE 0.125 +4.2% NRM 0.055 +0.0% BBB 0.520 −1.9% LGD 2.09 +1.9% DEC 0.110 +0.0% LCE 0.200 +0.0% NILI 0.515 −1.0% CDE 21.85 +6.7% CAN 0.045 +0.0% LORD 0.100 +0.0% HBM 29.49 +2.3% ELEF 0.265 +120.8% MUN 0.300 +0.0% SAGA 0.400 +6.7% Gold 4,079.60 −0.8% Silver 51.94 −0.8% Copper 6.24 −0.5% Oil 90.83 +0.3% Palladium 1,017.10 −2.6% KRN 0.260 −7.1% GSKR 2.84 +5.6% ADE 0.125 +4.2% NRM 0.055 +0.0% BBB 0.520 −1.9% LGD 2.09 +1.9% DEC 0.110 +0.0% LCE 0.200 +0.0% NILI 0.515 −1.0% CDE 21.85 +6.7% CAN 0.045 +0.0% LORD 0.100 +0.0% HBM 29.49 +2.3% ELEF 0.265 +120.8% MUN 0.300 +0.0% SAGA 0.400 +6.7%
Other Routine +

Pharmadrug, Pharmather to explore PD-001 for hantavirus

PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

By The Northwire Desk — AI Analysis May 13, 2026 · 10:08 PHRM · 0.085 Pharmather Holdings Ltd
Executive Summary
  • Headline: PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus.
  • Date: 2026-05-13.
  • Core Development: Independent research demonstrates cepharanthine inhibits Hantavirus pseudovirus (HTNVpv) in mouse models with high efficacy (~94% inhibition at 180 mg/kg/day).
  • Regulatory Status: Sairiyo Therapeutics received approval from an Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical study of PD-001 in healthy volunteers.
  • Objective: Evaluate safety, tolerability, pharmacokinetics, and bioavailability of the enteric-coated oral formulation (PD-001).
  • Ownership Structure: Sairiyo Therapeutics is 49% owned by PharmaTher Holdings Ltd. and 51% owned by Pharmadrug Inc.
  • Intellectual Property: PD-001 protected by US Patent US10576077 (expires March 23, 2036).
  • Historical Context: PD-001 was previously the subject of a $3.4 million contract from the Defense Threat Reduction Agency (DTRA) for Ebola virus-related research.
Material Impact
  • Pipeline Progression: The news confirms progression from preclinical mouse data to regulatory approval for Phase 1 human trials in healthy volunteers. This is a standard but necessary step for clinical validation.
  • Financial Impact: No immediate revenue generation or capital raise announced. The potential financial upside remains speculative and distant, contingent on successful Phase 1/2 results and eventual commercialization.
  • Market Expectations: Given the company's history of selling its primary cash-generating asset (Ketamine ANDA) in late 2025 for milestone payments, the market has already priced in a transition to pipeline monetization. This news is incremental rather than transformative.
  • Stock Price Reaction Context: The stock price has declined significantly from $0.54 (July 2025) to $0.09 (May 2026), despite the earlier announcement of the Ketamine ANDA sale ($25M+ potential). This suggests investor skepticism regarding the timing and certainty of future cash flows from pipeline assets.
  • Subsidiary Ownership: PharmaTher only owns 49% of Sairiyo, meaning the full financial benefit of any success is shared with Pharmadrug Inc., diluting the direct impact on PharmaTher's bottom line compared to a wholly-owned asset.
  • Risk Profile: Phase 1 healthy volunteer studies assess safety and bioavailability, not therapeutic efficacy in patients. Failure at this stage or subsequent stages would negate the value of the patent and research investment.
PHRM · Price
Company Overview
  • Company: PharmaTher Holdings Ltd. (PHRM).
  • Flagship Project: Ketamine-based therapies and delivery platforms.
    • Ketamine ANDA: Sold in late 2025 for potential >$25M consideration; retains profit-sharing rights.
    • Long-Acting Injectables (LAI): Partnership with Oakwood Laboratories for neuropsychiatric indications (Parkinson's, TRD).
    • Microneedle Patches: PharmaPatch™ platform targeting peptides, GLP-1s, and psychedelics.
  • Subsidiary Focus: Sairiyo Therapeutics (49% owned) focuses on Cepharanthine reformulations for viral infections (Hantavirus, previously Ebola).
  • Strategic Shift: Moving from generic asset monetization to proprietary platform development (AI discovery, patches, peptides).
Read the original news release →

More from Pharmather Holdings Ltd

May 27, 2026 · 08:01

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Other May 13, 2026 · 10:12

PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots

Other Apr 21, 2026 · 08:01

Strategic Alignment with Federal Psychedelic Mandate

Regulatory Apr 20, 2026 · 08:01

PharmaTher Seeks Regulatory Tailwinds Amidst Price Slump

Production / Operations Apr 16, 2026 · 08:01

PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

Regulatory Apr 13, 2026 · 08:01

PharmaTher Files Peptide Patch Patent as Stock Nears All-Time Lows Despite Pipeline Expansion

M&A / Property